Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfredo Halpern

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Expert Opinion on Drug Safety|December 23, 2014
Why are anti-obesity drugs stigmatized?Bruno Halpern, Alfredo Halpern
Expert Opinion on Drug Safety|January 8, 2015
Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medicationsBruno Halpern, Alfredo Halpern
Expert Opinion on Investigational Drugs|July 25, 2006
Investigational therapies in the treatment of obesityMarcio C Mancini, Alfredo Halpern
Treatments in Endocrinology|March 24, 2005
Diabesity: are weight loss medications effective?Alfredo Halpern, Marcio C Mancini
Arquivos Brasileiros De Endocrinologia E Metabologia|June 13, 2006
Pharmacological treatment of obesityMarcio C Mancini, Alfredo Halpern
Vascular Health and Risk Management|June 20, 2008
Orlistat in the prevention of diabetes in the obese patientMarcio C Mancini, Alfredo Halpern
Arquivos Brasileiros De Endocrinologia E Metabologia|January 29, 2015
Brown adipose tissue: what have we learned since its recent identification in human adultsBruno Halpern, Marcio Correa Mancini, Alfredo Halpern
Expert Review of Clinical Pharmacology|May 10, 2013
Fixed-dose combination of phentermine-topiramate for the treatment of obesityBruno Halpern, André M Faria, Alfredo Halpern
Drugs of Today (Barcelona, Spain : 1998)|August 19, 2011
Bupropion/naltrexone fixed-dose combination for the treatment of obesityB Halpern, A M Faria, Alfredo Halpern
Arquivos Brasileiros De Endocrinologia E Metabologia|January 16, 2007
[Case report: recently diagnosed celiac disease as aggravating factor of osteoporosis in an old woman]Camila C Pereira, Pedro Henrique S Corrêa, Alfredo Halpern
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Expert Opinion on Drug Safety|December 23, 2014
Why are anti-obesity drugs stigmatized?Bruno Halpern, Alfredo Halpern
Expert Opinion on Drug Safety|January 8, 2015
Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medicationsBruno Halpern, Alfredo Halpern
Expert Opinion on Investigational Drugs|July 25, 2006
Investigational therapies in the treatment of obesityMarcio C Mancini, Alfredo Halpern
Treatments in Endocrinology|March 24, 2005
Diabesity: are weight loss medications effective?Alfredo Halpern, Marcio C Mancini
Arquivos Brasileiros De Endocrinologia E Metabologia|June 13, 2006
Pharmacological treatment of obesityMarcio C Mancini, Alfredo Halpern
Vascular Health and Risk Management|June 20, 2008
Orlistat in the prevention of diabetes in the obese patientMarcio C Mancini, Alfredo Halpern
Arquivos Brasileiros De Endocrinologia E Metabologia|January 29, 2015
Brown adipose tissue: what have we learned since its recent identification in human adultsBruno Halpern, Marcio Correa Mancini, Alfredo Halpern
Expert Review of Clinical Pharmacology|May 10, 2013
Fixed-dose combination of phentermine-topiramate for the treatment of obesityBruno Halpern, André M Faria, Alfredo Halpern
Drugs of Today (Barcelona, Spain : 1998)|August 19, 2011
Bupropion/naltrexone fixed-dose combination for the treatment of obesityB Halpern, A M Faria, Alfredo Halpern
Arquivos Brasileiros De Endocrinologia E Metabologia|January 16, 2007
[Case report: recently diagnosed celiac disease as aggravating factor of osteoporosis in an old woman]Camila C Pereira, Pedro Henrique S Corrêa, Alfredo Halpern
Pageof 8